Comparative Antihypertensive Effects of Guanabenz and Clonidine

  title={Comparative Antihypertensive Effects of Guanabenz and Clonidine},
  author={Barry R. Walker and Larry E. Hare and M W Deitch},
  journal={Journal of International Medical Research},
  pages={14 - 6}
The safety and efficacy of guanabenz and clonidine were compared in 188 hypertensive patients during a 6-month double-blind trial. Mean supine diastolic blood pressure (SDBP) decreased from 103 to 88 mm Hg (p < 0.01) among guanabenz patients and from 101 to 88 mm Hg (p < 0.01) among clonidine patients who completed 6 months of b.i.d. therapy. Clinically significant individual SDBP decreases occurred in 85% of the guanabenz patients and in 83% of the clonidine patients after 6 months. Adverse… 
21 Citations

Figures and Tables from this paper

Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension: evaluation using home-based blood pressure measurements
Objective To clarify the effects of bedtime administration of the centrally acting α2-agonists, guanabenz and clonidine, on morning hypertension. Methods Patients with morning hypertension were
Use of centrally acting sympatholytic agents in the management of hypertension.
Even with the advent of newer antihypertensive agents, the centrally acting sympatholytics (alpha 2-adrenoceptor agonists) remain a valuable group of medications for the management of hypertension of all grades of severity.
Direct Vasodilators and Sympatholytic Agents
In contemporary practice, direct vasodilators and sympatholytic agents, particularly hydralazine and clonidine, are often utilized in refractory hypertension and may also serve as an alternative for patients with an intolerance to angiotensin antagonists.
Current assessment of the stepped-care treatment of mild hypertension: diuretics, beta-blockers, vasodilators versus Clonidine
The fairly conclusive demonstration by the Veterans Administration Cooperative Study Group on Antihypertensive Agents (1967) of the strikingly favourable effect of drug treatment on morbidity
Metabolic consequences of antihypertensive therapy
  • W.
  • Medicine
  • 1996
The angiotensin-converting enzyme inhibitor captopril is the first of a new class of antihypertensive agents that lower blood pressure as effectively as previous therapies without adversely affecting serum levels of total, highdensity lipoprotein, and low-densitylipoprotein cholesterol or triglyceride, glucose, or potassium levels.
Effects of Central Alpha-Adrenoceptor Agonists and Adrenergic-Neuronal Blocking Agents on the Kidney
The central alpha2-adrenergic agonists have qualitatively similar renal effects: relative preservation of renal function despite persistent reductions in systemic blood pressure, lack of clinically relevant effects on sodium excretion or body fluid composition, and absence of sustained effects on plasma renin activity.
Mediation of the hypotensive action of systemic clonidine in the rat by α2‐adrenoceptors
The data show that the hypotensive effect of intravenously administered clonidine results from activation of central α2‐adrenoceptors, with no significant contribution from an I1‐mediated effect.
Current Therapeutic Concepts in Diabetic Hypertension
The special problems in the treatment of hypertension within the diabetic population are now receiving greater attention and it has been suggested that the threshold for initiating antihypertensive therapy should be lower in diabetic patients.


Comparative antihypertensive effects of guanabenz and methyldopa.
Evidence of fluid retention, such as weight gain, edema, and congestive heart failure, was significantly more frequent with methyldopa than with guanabenz, which may be useful as sole initial antihypertensive therapy.
Long-term therapy of hypertension with guanabenz.
Guanabenz is safe and effective for initial and sole therapy of hypertension, with little change in any parameters other than improvement in mean SDBP to 85 mmHg and in individual response rate to 84%.
Effects of Placebo versus Guanabenz on Hypertensive Out-Patients
Guanabenz was an effective, well-tolerated drug, placebo effects on efficacy were significant, occurred early and remained stable, and placebo and guanabenz side effects were mainly sedation and dry mouth.
Guanabenz effects on blood pressure and noninvasive parameters of cardiac performance in patients with hypertension
Noninvasive parameters of cardiac performance in JO patients after single doses of guanabenz showed no significant changes and suggest that this new drug may be a useful antihypertensive agent that warrants further investigation.
Renal Effects of Guanabenz: A New Antihypertensive
The data suggest that the acute antinatriuresis is a transient hemodynamic event and chronic therapy with guanabenz will not be complicated by sodium retention, a feature characteristic of other antihypertensive agents.
Clonidine and the Kidney
  • H. Itskovitz
  • Medicine
    Journal of cardiovascular pharmacology
  • 1980
The effects of clonidine on renal hemodynamics and renal function make it a particularly useful antihypertensive agent and doses may have to be reduced because the drug is excreted chiefly by the kidney.
Evaluation of clonidine hydrochloride (Catapres). A new antihypertensive agent.
Clonidine hydrochloride is a new antihypertensive agent with a primary site of action in the central nervous system that is effective for long-term therapy and may be particularly useful in patients with moderately severe hypertension.
Effects of methyldopa on renal hemodynamics and tubular function
The data suggest that methyldopa, like other antihypertensives, reduces glomerular filtration rate and increases sodium retention.
Complications of antihypertensive therapy.
Effective use of modern antihypertensive agents requires an intimate understanding of the various side effects associated with each of the drugs. Some of the undesirable side effects are unavoidable
Surgery's relevance to an understanding of basic biology. Tissue repair and cellular regeneration.
In the introduction to this book J. D. Watson tells of the anxieties and concerns which he and Crick felt when they were first trying to elucidate the structure of DNA.